Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 7/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 5/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.31 |
| ▸ | HTR1A | P08908 | 4/20 | 0.31 |
| ▸ | HTR1B | P28222 | 4/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837326 | 0.96 | C5AR1 (0.39) | C5AR1AOC3PPARGPPARDPPARA | |
| SCHEMBL62935 | 0.90 | C5AR1 (0.43) | C5AR1AOC3SGPL1CHRM1 | |
| SCHEMBL62722 | 0.90 | C5AR1 (0.46) | C5AR1AOC3CHRM1LIMK2 | |
| SCHEMBL61195 | 0.89 | C5AR1 (0.43) | C5AR1SGPL1PPARGPPARDPPARA | |
| SCHEMBL61159 | 0.89 | C5AR1 (0.42) | C5AR1AOC3CHRM1 | |
| SCHEMBL63582 | 0.88 | C5AR1 (0.43) | C5AR1AOC3HTR1DSLC6A4HTR1A | |
| SCHEMBL61302 | 0.86 | C5AR1 (0.41) | C5AR1AOC3CHRM1 | |
| SCHEMBL64888 | 0.84 | C5AR1 (0.44) | C5AR1AOC3CHRM1LIMK2 | |
| SCHEMBL62058 | 0.83 | C5AR1 (0.41) | C5AR1AOC3CHRM1 | |
| SCHEMBL61134 | 0.83 | C5AR1 (0.42) | C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | claimed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C3AR1, C5AR1 | C5AR1 3/4885AOC3 652/4885SGPL1 3346/4885 |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C5AR1, C3AR1 | C5AR1 2/4885AOC3 690/4885SGPL1 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.